Provider Briefing: Aluminum Chloride Availability in 2026

If your patients have been reporting difficulty filling prescriptions for Aluminum Chloride Hexahydrate — most commonly prescribed as Drysol (20% topical solution) — you're not alone. Despite no formal FDA-listed shortage, real-world availability of this first-line hyperhidrosis treatment has been inconsistent throughout recent years.

This briefing covers the current supply landscape, prescribing considerations, cost and access factors, and tools you can use to help your patients find the medication they need.

Timeline: How We Got Here

Aluminum Chloride Hexahydrate has been a mainstay of hyperhidrosis management for decades. As a topical antiperspirant with a straightforward mechanism of action — forming a physical precipitate in the eccrine sweat ducts to block secretion — it has remained the first-line topical treatment recommended by the American Academy of Dermatology and the International Hyperhidrosis Society.

However, several converging factors have created intermittent supply disruptions:

• 2020-2023: Pandemic-related supply chain disruptions affected pharmaceutical manufacturing broadly, including niche topical products.
• 2023-2024: Consolidation among generic manufacturers and raw material sourcing challenges led to periodic stock-outs at retail pharmacies.
• 2025-2026: While manufacturing has largely stabilized, distribution inefficiencies and pharmacy stocking algorithms continue to create gaps in local availability. The product is manufactured but not always where patients need it.

Prescribing Implications

The intermittent availability of Aluminum Chloride has several implications for clinical practice:

Prescription Specificity

When writing prescriptions, consider these strategies to improve fill rates:

• Allow generic substitution: Writing for "Aluminum Chloride Hexahydrate 20% topical solution" rather than brand-name Drysol gives pharmacies more flexibility to fill from available stock.
• Specify concentration clearly: The 20% concentration is the standard prescription strength. The 6.25% and 12% formulations are available OTC (Certain Dri) and don't require a prescription.
• Include DAW 0: Dispense as written codes that restrict substitution can delay fills. Allow pharmacists to substitute equivalent generics when possible.

Compounding as a Backup

Aluminum Chloride Hexahydrate is an ideal candidate for compounding. The formulation is straightforward (aluminum chloride hexahydrate dissolved in anhydrous ethanol), and compounding pharmacies can prepare it in any clinically appropriate concentration. If your patient's retail pharmacy is out of stock, consider sending the prescription to a local compounding pharmacy.

Current Availability Picture

As of early 2026:

• FDA shortage status: Not listed on FDA Drug Shortage Database or ASHP shortage list
• Manufacturer status: Person & Covey (Drysol) continues to manufacture and distribute. Generic manufacturers remain active.
• Retail availability: Inconsistent. Chain pharmacies may not stock the product routinely. Independent pharmacies and compounding pharmacies tend to have better access.
• Patient reports: Many patients experience 1-2 week delays when their preferred pharmacy needs to special-order the medication.

Cost and Access Considerations

Aluminum Chloride remains one of the most cost-effective treatments in dermatology:

• Brand Drysol (20%, 35 mL): $22-$35 cash price
• Generic (20%, 35 mL): $10-$20 cash; $10-$13 with discount coupons
• Compounded: $15-$40 depending on concentration and pharmacy

Insurance coverage is variable. Many plans classify topical antiperspirants as cosmetic and do not cover them. Medicare Part D generally does not cover Drysol. However, the low cash price means most patients can afford the medication without insurance coverage.

There is no manufacturer patient assistance program from Person & Covey. Patients without insurance can use discount card programs (GoodRx, SingleCare, RxSaver) to access the lowest available price.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate availability challenges:

Medfinder for Providers

Medfinder allows providers and patients to check real-time pharmacy stock levels for Aluminum Chloride by location. You can direct patients to the platform to find pharmacies with current stock, eliminating the cycle of unsuccessful pharmacy visits.

Alternative Therapies to Consider

When Aluminum Chloride is unavailable or ineffective, the following evidence-based alternatives are available:

• Glycopyrronium Tosylate (Qbrexza): FDA-approved topical anticholinergic wipes for axillary hyperhidrosis in patients ≥9 years. Approximately $580/month; commercial insurance coverage is improving.
• OnabotulinumtoxinA (Botox): FDA-approved for severe axillary hyperhidrosis refractory to topical therapy. 50 units per axilla; retreatment at 6-12 month intervals. $1,000-$1,500 per session.
• Oral Glycopyrrolate: Off-label use for generalized hyperhidrosis. 1-2 mg BID-TID; titrate to effect. Affordable at $10-$30/month generic. Monitor for anticholinergic side effects.
• miraDry: FDA-cleared microwave thermolysis device for permanent reduction of axillary sweat glands. One-time procedure, $2,000-$3,000.

For a patient-facing comparison, you can share our alternatives guide with patients.

Looking Ahead

The supply situation for Aluminum Chloride is expected to remain stable but imperfect in 2026. The fundamental issue is not manufacturing capacity but distribution efficiency — the product exists but doesn't always reach the pharmacies where patients need it.

Providers can help by:

• Proactively discussing availability with patients at the point of prescribing
• Recommending Medfinder as a first step before patients start calling pharmacies
• Having compounding pharmacy referrals ready as a backup plan
• Maintaining familiarity with alternative therapies for when Aluminum Chloride is truly unavailable

Final Thoughts

Aluminum Chloride Hexahydrate remains the cornerstone of topical hyperhidrosis management — effective, well-tolerated, and affordable. While availability challenges persist, they are manageable with proactive planning and the right tools. By leveraging platforms like Medfinder, maintaining relationships with compounding pharmacies, and staying current on alternative therapies, you can ensure your patients with hyperhidrosis continue to receive the treatment they need.

For additional clinical resources, see our posts on Aluminum Chloride mechanism of action and drug interactions.